Analysis and ranking of TOP 25 pharma-based healthcare groups by business segment for revenues, sales, R&D costs and income
January 16, 2019 I We just released a management report for free download (see our menu „FREE reports“) in which…
How many PD-1 and PD-L1 checkpoint inhibitors do we need?
STUTTGART, Germany I June 19, 2018 I La Merie Publishing released the results of an independent search for and evaluation…
TCR Engineered T-Cells are coming out of the shadows and into the light
The next two years will give definitive clues about the prospects of this promising treatment modality for solid tumors STUTTGART,…
All time high of biologics sales in 2017 driven by cancer and innovative anti-inflammatory antibodies
STUTTGART, Germany I March 12, 2018 I Global sales of branded recombinant therapeutic antibodies and proteins in the calendar year…
Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-permeating biologics
STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are…
Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-penetrating biologics
STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are…
mRNA Vaccines & Therapeutics: are you ready to be on the ground floor of the next big new therapeutic modality?
STUTTGART, Germany I June 23, 2017 I Overlooked for many years, RNA languished as the ugly stepchild of nucleic acid…
2016 was another record year of biologics sales with therapeutic antibodies accounting for two-thirds of total biologics sales
STUTTGART, Germany I March 17, 2017 I Sales of branded originator biologics in 2016 continued to reach a record high…
Oncolytic Viruses: a still undervalued technology with strong growth perspectives
STUTTGART, Germany I January 25, 2017 I The acquisition of oncolytic virus company BioVex by Amgen in late 2011 for…
Beyond anti-CD19 CAR T-Cells: the future of CAR T-cells depends on the convergence of technologies
STUTTGART, Germany I August 10, 2016 I Immunotherapy of B-cell malignancies with specifically targeted autologous T-cells most probably will see…